Indication: Hematological Malignancies
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfitfor Intensive Chemotherapy
Sub-indication: Hematological Malignancies
Drug Study
Principal Investigator: Don Stevens, M.D.Norton Cancer Institute
Sponsor: Takeda Development Center Americas, Inc
Learn more at ClinicalTrials.gov
Email for more information: Heme-NCIResearch@nortonhealthcare.org
